|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13,444.00 GBX | -1.12% |
|
-1.09% | +28.43% |
| 12-12 | European health regulator recommends approval for GSK's twice-yearly asthma drug | RE |
| 12-12 | Weight-loss drug developers line up to tap lucrative market as competition heats up | RE |
Evolution of the Average Target: AstraZeneca PLC
Evolution of the Target Price: AstraZeneca PLC
Changes in Analyst Recommendations: AstraZeneca PLC
| Consensus | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Objective/dr gap | ||
|---|---|---|---|---|---|---|
 | +12.08% | |||||
| +4.69% | |||||
| -2.48% | |||||
| +9.63% | |||||
| +2.05% | |||||
| +2.06% | |||||
| +7.14% | |||||
| +22.46% | |||||
| +2.56% | |||||
| +9.47% | |||||
| Average | +6.97% | |||||
| Weighted average by Cap. | +5.76% |
Analysts' Consensus
Analyst Consensus Detail
Consensus revision (last 18 months)
Analysts covering the company
| JPMORGAN | Richard Vosser |
| BERNSTEIN RESEARCH | Justin Smith |
| JEFFERIES | |
| Morningstar | |
| alphavalue | Abhishek Raval |
| DEUTSCHE BANK RESEARCH | Emmanuel Papadakis |
| DZ BANK | Elmar Kraus |
| GOLDMAN SACHS | Rajan Sharma |
| UBS | Matthew Weston |
| BERENBERG | |
| BNP Paribas | |
| Svenska Handelsbanken | |
| Berenberg Bank | |
| BNP Paribas Exane | |
| AlphaValue/Baader Europe | |
| Morgan Stanley | |
| Carnegie Group | |
| Intron Health | |
| Deutsche Bank Securities | |
| Nordea Bank | |
| BARCLAYS | Emily Field |
| HSBC | |
| Stifel Nicolaus | |
| Jefferies & Co. | |
| Bernstein | |
| B. Riley | |
| RBC Capital Markets | |
| BMO Capital | |
| CREDIT SUISSE | Dominic Lunn |
| Argus | |
| Bank of America Securities/Merrill Lynch | |
| Danske Bank Group | |
| Kepler Capital Markets | |
| Kepler Cheuvreux | |
| DEUTSCHE BANK | Emmanuel Papadakis |
| SVB Leerink | |
| Bryan, Garnier & Co. | |
| Societe Generale | |
| Liberum Capital | |
| ODDO BHF | |
| BANK OF AMERICA (BOFA) | Sachin Jain |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- AZN Stock
- Consensus AstraZeneca PLC
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition